On Nov 05, major Wall Street analysts update their ratings for $Owens & Minor (OMI.US)$, with price targets ranging from $12.5 to $18.5.
BofA Securities analyst Allen Lutz maintains with a sell rating, and adjusts the target price from $16 to $12.5.
Citi analyst Daniel Grosslight maintains with a buy rating, and sets the target price at $18.5.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $18 to $14.
Baird analyst Eric Coldwell maintains with a hold rating, and adjusts the target price from $19 to $14.
Leerink Partners analyst Michael Cherny maintains with a hold rating, and adjusts the target price from $17 to $14.
Furthermore, according to the comprehensive report, the opinions of $Owens & Minor (OMI.US)$'s main analysts recently are as follows:
The company's Q3 results demonstrated a varied performance, with revenue matching expectations but segment profitability showing fluctuations. The company is persistently addressing its eligibility backlog which arose following the Change hack.
The company's third-quarter performance exceeded expectations but was counterbalanced by a reduction in profitability forecasts for fiscal 2024 and a negative free cash flow projection.
The company's recent quarter results showcased robust EBIT growth in its Patient Direct sector, which was somewhat offset by underperformance in Product & Health Services. The standout feature of the quarter was the notable operating margin in Patient Direct. However, there's growing concern regarding margin pressures within medical distribution, raising further questions about competitive movements in that area. This leads to a more cautious stance concerning the margin outlook leading up to 2025.
The assessment of Owens & Minor's third quarter performance indicated it met expectations with minimal surprises, and the initial negative reaction in the stock market was deemed excessive. The fourth quarter is anticipated to face challenges due to the residual impacts of hurricane activity on the company's PHS segment, which is likely to be somewhat balanced by a more robust Patient Direct segment. Additionally, cash flow is projected to experience a sequential improvement.
Here are the latest investment ratings and price targets for $Owens & Minor (OMI.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
